期刊
EXPERT REVIEW OF ANTICANCER THERAPY
卷 11, 期 8, 页码 1277-1282出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.11.112
关键词
anastrozole; aromatase inhibitors; chemoprevention trials; cognitive dysfunction; diffusion tensor radiological imaging; estrogen receptor; exemestane; letrozole; neurological functional imaging; neuropsychological testing; postmenopausal; tamoxifen
类别
As mortality in breast cancer patients has improved, morbidity of treatment has become increasingly important. Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor-positive breast cancer patients. Chemotherapy has been associated with cognitive dysfunction through neuropsychological testing and neurological functional imaging, but the relationship between estrogen and cognition remains largely unexplained. In focusing on aromatase inhibitor therapy, most of the studies yielding mixed results have been limited by confounders and small numbers of populations studied. This article briefly summarizes the major studies evaluating aromatase inhibitor therapy and cognitive dysfunction while considering new directions in future study design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据